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Abstract: A benzene-poly-carboxylic acid complex with cis-diammineplatinum(II) dihydro-
cholride, BP-C1 is currently used in clinical trials in treating metastatic breast cancer. BP-C1 
controls tumor growth with a few mild side-effects, improving quality of life.
Methods: The data consisted of prospectively collected laboratory results from 47 patients in 
two controlled clinical trials of daily intramuscular injections of BP-C1 for 32 days. Study I 
was performed as an open, nonrandomized, Phase I dose–response, multicenter study with a 
three-level, between-patient, response surface pathway design. The second study was a random-
ized, double-blind, and placebo-controlled, multicenter study with a stratified semi-crossover 
design.
Results: Hemoglobin (Hb) and hematocrit (Hct) increased significantly (P0.01) during 
BP-C1 treatment, while red blood cell (RBC) count increased but not significantly. The most 
pronounced increase in Hb, RBC, Hct, and white blood cell (WBC) was in anemic patients 
(P0.01). WBC count and neutrophils increased significantly (P=0.01) in the overall data. 
WBCs and neutrophils (P0.01), eosinophils (P=0.05) and monocytes (P0.01) increased 
significantly and markedly in patients with lowest baseline levels. Additionally, low levels of 
thrombocytes significantly increased. No changes in liver parameters, amylase, glucose, crea-
tinine, or albumin, were detected except for albumin in the subgroup with low baseline levels, 
where levels increased significantly (P=0.04). An increase in K+, Ca2+, and PO
4
3- was most 
pronounced in patients with low baseline levels (P0.02). A similar pattern detected for Mg2+, 
prothrombin time (PT), coagulation factors II, VII, X (KFNT), and C-reactive protein (CRP), 
which increased significantly (P0.05) in the groups with the lowest values.
Conclusion: Our findings support the safety profile of BP-C1 use in cancer patients. BP-C1 
did not induce anemia, infection, bleeding, hepatic insufficiency or electrolyte imbalances. 
In contrast, BP-C1 corrected abnormalities. No hematological and biochemical toxicity was 
observed.
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Introduction
Low blood cell count is a known complication during cancer treatment.1,2 The European 
Cancer Anemia Survey (ECAS) evaluated the prevalence, incidence, and treatment 
of anemia in cancer patients.3 Data from 15,367 patients included tumor type, perfor-
mance status, hemoglobin (Hb) levels, and cancer treatments. Prevalence of anemia 
at enrollment was 39.3% and was 67.0% during the survey, while the incidence of 
anemia was 53.7%, of which, 38.9% were treated. Anemia significantly correlates with 
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poor performance status, which is compounded by the fact 
that many anemic patients remain untreated for their anemia. 
There are different causes of anemia amongst cancer patients: 
a prior low Hb level before the development of cancer, the 
cancer itself, and cancer treatments, such as radiotherapy and, 
more significantly, platinum-based chemotherapy. Anemia 
has been shown to be a useful biomarker in patients treated 
with rituximab-CHOP (combining cyclophosphamide, 
hydroxydaunorubicin, oncovin, and prednisone or predni-
solone) immunotherapy.4
About 33% of cancer patients experience an infection as 
a result of chemotherapy, of which 57% are associated with 
neutropenia. This suggests that the risk of neutropenia has 
a significant impact on patients’ clinical care and quality of 
life (QoL). Neutropenia is a common and potentially life-
threatening side effect of some chemotherapeutic regimens, 
due to the heightened risk of infection.5,6
Thrombocytopenia can be caused by bone marrow 
suppression, as a side effect of chemotherapeutic drugs 
or as a direct consequence of cancer (ie, infiltration of 
the bone marrow, which results in impaired production of 
platelets). Thrombocytopenia can be a serious complica-
tion.7 Within a cohort of 609 patients with solid tumors or 
lymphoma, bleeding occurred during 9% of cycles among 
patients with previous bleeding episodes (P0.0001). 
Major bleeding episodes resulted in shorter survival and 
higher resource utilization (P0.0001). Overall, the 
incidence of bleeding is low among patients with solid 
tumor; however, within some subgroups, the incidence 
exceeds 20%. Poor response to platelet transfusion is a 
clinically and financially significant downstream effect of 
thrombocytopenia.
The liver has a key role in the metabolism of many com-
monly used anticancer agents.8 Thus liver function assessment 
is a fundamental part of initial and ongoing management of 
patients with cancer. Chemotherapy in the setting of liver 
dysfunction can be associated with reduced effectiveness. Fur-
thermore, several chemotherapy agents induce liver injury or 
dysfunction, which can manifest as abnormal serum liver bio-
chemistry. Conventional serum liver biochemical testing does 
not always predict these potential complications. In the present 
study, we focused on current standard serum liver biochemical 
testing, measurements of liver physiology and pathophysiol-
ogy, because of their limitations for chemotherapy dosing. 
This study highlighted the effect of treatment with benzene-
poly-carboxylic acid complex with cis-diammineplatinum(II) 
(BP-C1) on serum liver biochemistry, in patients with stage 
IV metastatic breast cancer (MBC).
Increasing evidence links electrolyte disorders with 
greater morbidity and mortality, in critically ill patients. 
There are very few guidelines on the treatment of elec-
trolyte disorders in critically ill patients,8,9 and most focus 
on individual electrolytes without taking the interrelation 
between specific deficits into account. Hyperkalemia, hyper-
calcemia, and hyponatremia can be chemotherapy-induced 
via various factors, for example, tumor lysis syndrome can 
cause hyperkalemia. Hypercalcemia and hyponatremia 
are often observed in patients with breast cancer, prostate 
cancer, and paraneoplastic syndrome. Hypercalcemia can 
also result from osteolysis but is mainly hormone-induced, 
such as in the case of parathyroid hormone-related protein. 
In some cases, hypomagnesemia results from drugs target-
ing epidermal growth factor receptors, such as cetuximab 
and panitumumab. Small-molecule targeted drugs, such as 
m-TOR inhibitors and ABL kinase inhibitors, can cause 
hypomagnesemia and hypophosphatemia. Thus, careful 
monitoring of the serum electrolyte concentration plays 
an important part in the biochemical monitoring of cancer 
patients and ensures effective and safe chemotherapy dosing 
in cancer, which is currently poorly defined. The purpose of 
our present investigation was to determine the effect of a 
new anticancer substance, BP-C1, which contains a very low 
content of cis-diammineplatinum(II) dichloride, on abnormal 
hematological and biochemical levels in stage IV MBC.10
Methods
study design and participants
Prospectively collected laboratory results were obtained from 
47 patients suffering from stage IV MBC, in two controlled 
clinical trials of daily intramuscular (IM) BP-C1 treatment 
for 32 days.11,12 Study 1 was performed as an open, nonran-
domized, Phase I dose–response, multicenter study with a 
three-level, between-patient, response surface pathway (RSP) 
design.13 Of the 47 MBC patients, 15 were of Asian origin. 
According to the RSP design, five of the patients received a 
daily injection of 0.02 mg/kg BP-C1, one received 0.0256 mg/
kg, one received 0.0275 mg/kg, one received 0.03 mg/kg, and 
four received 0.035 mg/kg. The mean age and body weight 
were 51.2 years (range 37–67 years) and 57.3 kg (range 
45.3–78.0 kg) (Table 1). The patients had undergone from 
three to nine prior chemotherapy treatment cycles without 
known therapeutic effects. Study 2 was performed as a ran-
domized, double-blind, and placebo-controlled, multicenter 
study, with a stratified semi-crossover design.14,15 The patient 
cohort consisted of 29 European and three Asian female MBC 
patients. All the patients received one daily IM injection 
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of 0.035 mg/kg BP-C1 over 32 days. The mean age and 
body weight were 56.3 years (range 34.2–72.6) and 74.0 kg 
(range 44.0–101.0) (Table 1). All the included patients had 
previously undergone at least third-line chemotherapy and 
several other available types of cancer treatments.
Procedures
Blood samples were taken at baseline (within 1 week prior to 
the BP-C1 treatment) and on the day after the end of BP-C1 
treatment. Blood was drawn via a cubital vein and separated 
into serum by centrifugation. Standard procedures for mea-
surement of the different parameters were used according 
to the standard methodology of the participating hospitals. 
All patients received one daily IM injection over 32 days. 
Approval of the ethical committees and the medical agen-
cies in the participating countries were received, along with 
written consent from all patients.
statistical analysis
The results were expressed as mean value (standard deviation 
[SD]) and 95% confidence interval (CI) of the mean. For each 
of the observed variables, the quartiles were calculated. The 
25Q, representing the upper limit of the first quartile (Q1) (the 
lower 25% of the observed data), and the 75Q, representing 
the lower limit of the fourth quartile (Q4) (the upper 25% of 
the observed data) were also calculated.
Changes from baseline to 32 days of treatment was cal-
culated with paired Student’s t-test.15
The correlation coefficients (r) with 95% CI refer to 
Pearson linear correlation and the coefficients (β0 and β1) 
in the linear regression analysis.16 Fisher z- transformation 
was used for testing and CI calculations.16 The increase 
from baseline to the end of BP-C1 treatment was cor-
related, and linear regression between the dependent 
increase during treatment and the independent baseline 
was performed.
Outcomes
The study outcomes were hematological and biochemical 
values, recorded after 32 days of BP-C1 treatment.
Results
hematology
Hb, white blood cell (WBC), and hematocrit (Hct) levels 
increased significantly (P0.01) during the 32 days of treat-
ment. Red blood cells (RBCs) increased during the same 
period but not significantly (Table 2). Mean cell volume 
(MCV) and ferritin levels were unchanged during treatment. 
The increase in Hb, WBC, Hct, and RBC was significantly 
(P0.01) most pronounced among the patients in the 
Q1 subgroup, ie, with lowest baseline levels. No significant 
changes were detected among patients in the Q4 subgroup, ie, 
with highest baseline levels (Figure 1). Significant negative 
correlations (P0.01) were detected between the increase 
during the 32 days of treatment, and the baseline, for Hb, 
RBC, WBC, and Hct (Table 3).
In the overall data, thrombocyte count was nearly unchanged 
during 32 days of BP-C1 treatment. However, a significant 
increase (P=0.02) was detected in the Q1 subgroup and 
a significant reduction (P=0.02) in the Q4 subgroup (Table 2). 
Significant negative correlations (P0.01) were detected 
between the increase at day 32, and the baseline, for 
Table 1 Demographic data
Factor Study 1 (n=15) Study 2 (n=32)
Mean (SD) Min – max Mean (SD) Min – max
Demographic factors and vital signs
age (years) 51.2 (7.8) 37.0–67.2 56.3 (9.8) 34.2–72.6
BMi (kg/m2) 23.6 (3.2) 17.9–29.4 28.3 (5.2) 20.1–38.3
Disease duration (year) 5.4 (4.5) 1.8–18.0 6.6 (4.5) 1.1–19.0
systolic BP (mmhg) 119 (12.6) 95–143 130 (10.9) 104–150
Diastolic BP (mmhg) 78 (9.7) 48–90 79 (8.1) 51–90
heart rate (beat/min) 79 (10.8) 73–85 81.2 (9.0) 68–115
respiratory rate (breath/min) 18 (2.3) 12–22 17.2 (1.8) 14–22
Previous cancer treatment
surgery 13/15 28/32
chemotherapy 15/15 32/32
hormone therapy 9/15 25/32
antibody therapy 0/15 4/32
radiotherapy 4/15 23/32
Others 0/15 4/32
Abbreviations: BMi, body mass index; BP, blood pressure; sD, standard deviation.
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 thrombocytes (Table 3). There was a significant increase in 
neutrophils (P=0.01), no significant increase in eosinophils, 
and a nearly unchanged basophil and monocyte count in 
the overall data (Table 2). In the subgroup Q1, significant 
increases in neutrophils (P0.01), eosinophils (P=0.045), 
and monocytes (P0.01) were detected. No significant 
changes were found in the Q4 subgroup (Figure 1). Signifi-
cant negative correlations (P0.01) were detected between 
the increase during the 32 days of BP-C1 treatment and the 
baseline level for neutrophils, eosinophils, and monocytes 
(Table 3). Lymphocyte levels decreased significantly during 
32 days of BP-C1 treatment in the overall data. However, 
a borderline significant increase (P=0.08) was detected in 
the Q1 subgroup, while a significant decrease (P=0.01) was 
found in the Q4 subgroup, and a significant negative correla-
tion (P0.01) was found between increase in the lympho-
cytes during 32 days and the baseline level (Table 3).
serum chemistry
Gamma-glutamyltransferase (GGT), lactate dehydrogenase 
(LDH), and alkaline phosphatase (ALP) increased slightly but 
not significantly during 32 days of BP-C1 treatment in the overall 
data. A similar pattern was detected in both Q1 and Q4 (Table 4)
subgroups. In the overall data, alanine aminotransferase (ALT) 
increased borderline significantly (P=0.08) during treatment. 
The increase in ALT was most pronounced and significant 
(P=0.04) among the Q1 patients. A nonsignificant reduction 
was detected in the Q4 subgroup, and a significant positive 
correlation (P0.01) was detected between the increase during 
32 days of treatment and ALT baseline (Table 3).
In the overall data, no change in amylase and glucose 
was detected during the 32-day BP-C1 treatment (Table 4). 
A significant increase in amylase (P=0.04) was detected 
among patients in the Q1 subgroup, and a significant reduction 
(P=0.02) was found in the Q4 subgroup. Significant negative 
correlations (P0.01) were detected between increase dur-
ing 32 days treatment and the baseline amylase (Table 3). 
No significant changes in creatinine, albumin, or bilirubin 
were detected in the overall data. For albumin, the Q1 sub-
group showed a significant increase (P=0.03) (Table 4). The 
Q1 subgroup analysis also detected a borderline significant 
increase in bilirubin (P=0.06), but no change in creatinine. 
No significant changes were detected for bilirubin and crea-
tinine in the Q4 subgroup. The increase in albumin during 
BP-C1 treatment was significantly (P0.01) negatively cor-
related to the baseline (Figure 2). K+, Ca2+, and PO
4
3- increased 
significantly (P0.03) during treatment, in the overall data. 
The increases in K+, Ca2+, and PO
4
3- were most pronounced 
Table 2 change in hematological values from baseline to day 32 of BP-c1 treatment, for the overall data and for patients in the lower 
quartile
Overall data (n=47) P-value First quartile ( n=12) P-value
Baseline 32 days Baseline 32 days
hemoglobin (g/l) 120.4 124.2 P=0.01 105.5 117.0 P0.01
116.7–124.1 120.7–127.8 100.8–110.2 108.5–125.5
red blood cell count (106/µl) 4.1
3.9–4.3
4.2
4.1–4.3
P=0.20 3.5
3.2–3.8
3.8
3.5–4.1
P0.01
hematocrit (%) 36.9 37.8 P=0.01 32.4 34.8 P=0.02
35.8–37.9 36.8–38.9 30.7–34.2 32.2–35.5
Mean cell volume (fl) 90.9 89.4 P=0.24 81.2 80.9 P=0.73
88.1–93.8 86.7–92.1 75.5–87.0 74.9–86.8
Platelet count (109/l) 256.2 247.5 P=0.40 166.0 207.8 P=0.02
231.5–280.8 225.0–270.0 145.7–186.3 168.3–247.4
White blood cell count (109/l) 5.82 6.51 P=0.01 3.70 5.96 P0.01
5.23–6.41 5.95–7.08 3.48–3.92 4.77–5.14
neutrophils (%) 58.3 61.5 P=0.01 46.7 53.9 P0.01
55.7–61.0 59.0–64.0 44.0–49.4 49.4–58.5
eosinophils (%) 2.37 2.90 P=0.16 0.41 1.86 P=0.05
1.70–3.03 2.10–3.69 0.16–0.66 0.47–3.26
Basophils (%) 0.33 0.34 P=0.86 0.00 0.12 P=0.10
0.21–0.45 0.23–0.46 –* 0.00–0.27
Monocytes (%) 7.61 6.95 P=0.12 5.06 6.61 P0.01
8.85–8.37 6.37–7.54 4.46–5.66 5.72–7.49
lymphocytes (%) 30.9 28.1 P=0.02 21.2 25.0 P=0.08
28.5–33.3 25.7–30.4 18.8–23.7 19.8–30.2
Notes: BP-C1, benzene-poly-carboxylic acid complex with cis-diammineplatinum(II); *all values equal 0. The results are expressed as mean values and 95% confidence 
intervals.
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among the patients in the Q1 subgroup (P0.01) (Table 4). 
In the Q4 subgroup, PO
4
3- increased significantly (P=0.04), 
but no changes were detected for K+ and Ca2+ (Figure 2). No 
significant change in Mg2+ was detected in the overall data, but 
this increased significantly (P=0.01) in the Q1 subgroup. The 
increase in Mg2+ during treatment was significantly (P0.01) 
negatively correlated to baseline (Table 3).
The prothrombin time (PT), KFNT, and C-reactive 
protein (CRP) were nearly unchanged during treatment in 
the overall data (Table 4). In the Q1 subgroup, PT, KFNT, 
and CRP increased significantly (P0.05), whereas KFNT 
was significantly reduced (P0.01) among the Q4 patients. 
The increase in KFNT during treatment was significantly 
(P0.01) negative correlated to baseline (Table 3). No such 
correlation pattern detected for PT or CRP.
Discussion
A Phase I study demonstrated the clinical therapeutic 
benefit of BP-C1 in MBC,11 as did a Phase II randomized, 
double-blind, placebo-controlled, multicenter study with 
semi-crossover design.12 When 0.035 mg/kg BP-C1 was 
delivered intramuscularly for 32 days, it was found effec-
tive and also safe to use. Patients who completed 32 days 
of BP-C1 treatment were offered to continue BP-C1 (ie, 
open-label use) for an additional 32 days. In the Phase I 
study, 62.5% were classified as responders, with one patient 
a complete responder. The toxicity Bethesda NCT/CTC 
 version 2.017 increased in the low-dose group, but decreased 
in the high-dose group. In the Phase II study, the sum of 
target lesions increased by 2.4% in the BP-C1 group and 
by 14.3% in the placebo group. The increase in the placebo 
group was significant but was not in BP-C1. The difference 
between the groups was significant, in favor of BP-C1. There 
was a significant difference in favor of BP-C1 with respect 
to RECIST classification. The sum CTC-NCI toxicity score 
increased nonsignificantly in the BP-C1 group but increased 
significantly in the placebo group. The increase difference 
did not meet the level of significance. The sum toxicity score 
Figure 1 Hematology findings: regression between the increase from baseline to day 32 of BP-C1 treatment, and baseline.
Notes: The full line represents the estimated regression line, the shaded area represents the 95% confidence interval of the regression line, and the dotted line represents 
the 95% prediction interval. The observed values are given as circles.
Abbreviation: BP-c1, benzene-poly-carboxylic acid complex with cis-diammineplatinum(ii).
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decreased in the patients receiving 64 days of BP-C1, from 
9.2 at screening to 8.9 at day 48, but increased again to 10.1 
and 10.6 during follow up. There was significant difference 
in favor of BP-C1. Patient responses of “Breast cancer treat-
ment problem last week” was significantly decreased in the 
BP-C1 group and slightly increased in placebo. “Breast 
cancer related pain and discomfort” and “Physical activ-
ity problem” was significantly reduced during the 64 days 
of BP-C1 treatment. Thus these two clinical trials show a 
promising effect of BP-C1 for stage IV MBC patients.
We searched PubMed for reports published in English 
up to September 30, 2014, for chemotherapy agents 
preventing hamatological and biochemical disturbances 
as well as for nonchemotherapy agents to relieve side 
effects.18 We assessed all relevant articles for quality and 
relevance.19–24 Drug treatment requiring hospitalization or 
with known adverse effects and toxicity and no efficacy 
were not included in this systemic review, such as erythro-
poietin, platelet transfusion, electrolyte infusion or albumin 
infusion. It has been shown that primary prophylaxis with 
G-CSF in chemotherapy for epithelial ovarian cancer is of 
low significance.19 Docetaxel-loaded solid lipid nanoparticles 
(DSNs) have been developed to reduce systemic toxicity of 
docetaxel while still keeping its anticancer activity. More-
over, DSNs were shown to improve the main side effects of 
Taxotere® by greatly lowering myelosuppression toxicity 
to bone marrow cells, in mice. These findings can be used 
to develop DSNs for human use.20 Treatment of cancer 
patients with herbo-mineral and metallic Ayurvedic drugs 
has been reported to significantly reduce the toxic effects of 
chemotherapy on various symptoms, and to have improved 
QoL,21,22 although no positive effects on hematological 
parameters could be demonstrated. Various herbal medi-
cines have also been tested in cancer patients treated with 
chemotherapy, and these have been used to reduce chemo-
therapy-induced nausea and vomiting, to improve patients’ 
QoL and to allow their subsequent chemotherapy. But 
again, the effect of adjuvant herbs on hematological and/or 
biochemical imbalances were not tested.23,24 Results of the 
literature review suggest that there are a very limited amount 
of scientifically supported reports on the effect of innovative 
nontoxic drugs to alleviate chemotherapy- or cancer-induced 
toxicity with respect to hematological and/or biochemical 
imbalances (which potentially causes harm to our patients). 
Hopefully, drugs, such as BP-C1, will be developed to pro-
tect patients against cancer- and/or chemotherapy-induced 
toxicity in the future, thereby reducing serious cancer- and/or 
chemotherapy-induced complications, such as infections, 
anemia, bleedings, cachexia, and cardiovascular complica-
tions. In this context, BP-C1 seems to be an effective and 
a well-tolerated substance for patients with stage IV MBC, 
irrespective of previous chemotherapy treatment.
The promising effect of BP-C1 on patients with stage IV 
MBC is further substantiated in the present study, which clearly 
demonstrated that BP-C1 is superior to chemotherapy drugs 
concerning changes in hematology and biochemistry levels.1,3,5–7 
The breaking news is that BP-C1 corrects these levels in MBC 
patients with low baseline values after chemotherapy. It is well 
known that chemotherapy drugs and some biological therapies 
can reduce patients’ RBC, WBC, and platelet counts substan-
tially. Further, tumor lysis syndrome can occur secondary to 
Table 3 correlation between increase during the 32-day 
treatment and baseline
Hematology Serum chemistry
hemoglobin -0.43 ϒ-gT 0.16
-0.64 to -0.16 -0.13 to 0.44
rBc -0.57
–0.73 to -0.33
lDh 0.40
0.12 to 0.62
hematocrit -0.36 alP -0.03
-0.59 to -0.08 -0.31 to 0.26
McV -0.33 amylase -0.72
-0.57 to -0.05 -0.84 to -0.55
Platelet count -0.51 glucose -0.14
-0.69 to -0.26 -0.42 to 0.15
WBc -0.48 creatinine -0.29
-0.67 to -0.22 -0.53 to -0.01
neutrophils -0.49 albumin -0.36
-0.68 to -0.23 -0.59 to -0.08
eosinophils -0.36 Bilirubin -0.21
-0.59 to -0.08 -0.47 to 0.08
Basophiles -0.47 Urea 0.28
-0.67 to -0.21 -0.01 to 0.52
Monocytes -0.73 Potassium -0.56
-0.84 to -0.56 -0.73 to -0.33
lymphocytes -0.49
-0.68 to -0.23
sodium -0.39
-0.61 to -0.12
calcium -0.72
-0.88 to -0.65
Magnesium -0.51
-0.70 to -0.25
Phosphate 0.20
-0.10 to 0.47
PT -0.72
-0.83 to -0.54
KFnT -0.69
-0.82 to -0.50
crP 0.05
-0.26 to 0.35
Note: The results were expressed as the Pearson linear correlation coefficient with 
95% confidence interval (using the Fisher z-transformation).
Abbreviations: alP, alkaline phosphatase; crP, c-reactive protein; lDh, lactate 
dehydrogenase; KFnT, coagulation factors ii, Vii, X; McV, mean corpuscular volume; 
PT, prothrombin time; rBc, red blood cell; WBc, white blood cell; ϒ-gT, γ-glutamyl 
transferase.
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Table 4 change in serum chemical values from baseline to day 32 of BP-c1 treatment, for the total data and for patients in the lowers 
quartiles
Overall data (n=47) P-value First quartile (n=12) P-value
Baseline 32 days Baseline 32 days
ϒ-gT (U/l) 58.3 159.3 0.11 17.0 45.6 0.16
33.3–83.2 27.8–290.7 14.8–19.2 3.3–88.0
lDh (U/l) 480.6
317.4–643.9
690.6
373.4–1,007.7
0.05 259.4
240.0–278.7
632.6
0–1,415
0.32
alP (U/l) 192.9 327.7 0.22 77.0 86.8 0.11
158.2–277.7 107.7–547.7 62.5–91.5 71.1–101.2
alT (U/l) 24.29
19.27–29.31
34.95
20.35–49.56
0.08 11.16
10.20–12.12
21.44
11.61–31.27
0.04
amylase (U/l) 74.1 73.0 0.88 28.3 38.3 0.04
54.3–93.9 59.4–86.6 24.1–32.5 28.0–48.7
glucose (mmol/l) 5.82 5.93 0.59 4.78 4.79 0.98
5.43–6.20 5.41–6.45 4.54–5.02 4.38–5.19
creatinine (µmol/l) 73.4 73.9 0.83 52.3 54.5 0.60
68.1–78.8 67.9–79.9 49.9–54.7 44.1–64.9
albumin (g/l) 45.1 44.7 0.57 39.3 42.1 0.04
43.7–46.5 43.3–46.2 38.3–40.3 40.0–44.2
Bilirubin (µmol/l) 10.1 13.0 0.45 6.0 7.7 0.06
8.8–11.5 5.6–20.4 5.3–6.8 6.1–9.4
Urea (mmol/l) 7.42 9.42 0.003 4.14 4.76 0.07
6.29–8.55 7.59–11.34 3.74–4.55 3.95–5.56
Potassium (mmol/l) 4.15 4.31 0.03 3.69 4.17 0.002
4.03–4.28 4.19–4.44 3.55–3.83 3.91–4.42
sodium (mmol/l) 140.7 140.3 0.51 136.3 137.3 0.32
139.4–142.0 138.8–141.7 135.2–137.4 135.5–139.0
calcium (mmol/l) 2.33 2.38 0.21 2.17 2.38 0.003
2.25–2.40 2.33–2.43 2.12–2.21 2.75–2.48
Magnesium (mmol/l) 1.15 1.12 0.42 0.77 0.82 0.01
0.98–1.34 0.98–1.27 0.75–0.79 0.78–0.87
Phosphate (mmol/l) 1.92 2.16 0.001 0.92 1.15 0.004
1.53–2.32 1.72–2.61 0.87–0.97 1.01–1.29
PT 13.78 13.3 0.17 11.12 11.74 0.05
13.00–14.55 12.75–13.85 10.66–11.59 10.87–12.61
KFnT 1.00 0.97 0.10 0.89 0.94 0.02
0.97–1.02 0.95–1.00 0.87–0.92 0.91–0.97
crP (mg/l) 5.06 7.49 0.34 0.89 2.92 0.008
3.30–6.52 2.00–12.94 0.49–1.30 1.61–4.22
Note: The results are expressed as mean values with 95% confidence intervals.
Abbreviations: alP, alkaline phosphatase; alT, alanine transaminase; BP-c1, benzene-poly-carboxylic acid complex with cis-diammineplatinum(ii); crP, c-reactive protein; 
lDh, lactate dehydrogenase; KFnT, coagulation factors ii, Vii, X; PT, prothrombin time; ϒ-gT, ϒ-glutamyl transferase.
chemotherapy, in which killed cancer cells are broken down 
by the body, causing hyperuricemia, hyperkalemia, hyperphos-
phatemia, and hypocalcemia.18 Shibata has recently underlined 
the importance of careful monitoring of serum Mg2+ and PO
4
3- 
ions in patients treated with small-molecule targeted drugs, to 
which small attention has been paid so far.25
Levels of K+, Na+, and PO
4
3- must be maintained within a 
very narrow margin to avoid arrhythmia and kidney failure. 
Furthermore, the majority of cancer patients undergoing 
chemotherapy develop anemia during their treatment. The 
ECAS, a study conducted across 24 nations in Europe, 
reported that about 83% of patients who received chemo-
therapy demonstrated anemia.3 Anemia often increases 
symptoms such as fatigue, weakness, and dyspnea; thus, it 
may worsen QoL and performance status in cancer patients. 
Anemia can also affect the prognosis of cancer patients, 
resulting in higher mortality. Chemotherapy-induced anemia 
in cancer patients is often underestimated and is not appro-
priately treated by health care providers. The ECAS showed 
that 53% of cancer patients did not receive any treatment 
for their anemia. BP-C1 seems to be the drug of choice to 
prevent anemia, neutropenia, and tumor lysis syndrome, 
thereby improving physical/nonphysical functioning, QoL, 
and prognosis in cancer patients. However, larger trials are 
necessary comparing BP-C1 with classical chemotherapy 
drugs on this matter.
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Figure 2 Clinical chemistry findings: regression between the increase from baseline to day 32 of BP-C1 treatment, and baseline.
Notes: The full line represents the estimated regression line, the shaded area represents the 95% confidence interval of the regression line, and the dotted line represents 
the 95% prediction interval. The observed values are given as circles.
Abbreviation: BP-c1, benzene-poly-carboxylic acid complex with cis-diammineplatinum(ii).
 $OEXPLQ &DOFLXP
6RGLXP3RWDVVLXP



±
±


±
±
±
±
±





±
      
%DVHOLQH%DVHOLQH
%DVHOLQH%DVHOLQH
'D\
±
EDV
HOLQ
H
'D\
±
EDV
HOLQ
H
'D\
±
EDV
HOLQ
H
'D\
±
EDV
HOLQ
H
 
          
Systemic infections are frequent and a serious compli-
cation in neutropenic patients.26 Preventing neutropenia 
is extremely important to achieve a successful outcome 
for patients undergoing chemotherapy. In contrast to most 
chemotherapy drugs, health care professionals can admin-
ister BP-C1 in the patients’ own home, and BP-C1 is not 
associated with neutropenia, thereby avoiding the need 
for human recombinant G-CSF that is used to treat neu-
tropenia after chemotherapy.27,28 As stated by Hurvitz et al 
chemotherapy-related adverse effects in MBC are associ-
ated with a substantial economic burden for society, which 
increases with the number of adverse effects reported.29 With 
none or fewer complications associated with BP-C1 treatment, 
the financial impact may be eliminated. BP-C1 is not associ-
ated with low thrombocyte counts and was able to normalize 
the thrombocyte count after chemotherapy, in contrast to other 
anticancer drugs.30 Electrolyte imbalance correction, includ-
ing that of serum albumin in patients with hypoalbuminemia, 
was observed after chemotherapy and BP-C1.
According to Kayl and Meyers, chemotherapy and its 
associated side effects can result in cognitive dysfunction 
with an adverse effect on QoL.31,32 In contrast, this has 
never been observed with BP-C1. In order to understand the 
mechanism of actions behind these surprising and extremely 
positive effects of BP-C1 on hematological and biochemical 
abnormalities in cancer patients, we are currently carrying 
out genetic studies on MBC patients.33
Conclusion
BP-C1 seems to be the drug of choice to prevent anemia, 
neutropenia, tumor lysis syndrome, and biochemical 
imbalances, to improve physical as well as nonphysical 
function, QoL, and prognosis in cancer patients.
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